Clinical Trial

Clinical Study of Universal CD19 CAR-γδT Cell Injection in the Treatment of Adult Relapsed/Refractory B-cell Lymphoma

Name: Clinical Study of Universal CD19 CAR-γδT Cell Injection in the Treatment of Adult Relapsed/Refractory B-cell Lymphoma — clinical trial record (NCT07367685)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

This study is an open-label, single-arm clinical trial designed to evaluate the safety and tolerability of QH103 cell injection solution in adult subjects with relapsed/refractory CD19-positive B-cell lymphoma.

Trial Details

NCT Number	NCT07367685
Lead Sponsor	The Second Affiliated Hospital of Fujian Medical University
Conditions	Recurrent/Refractory B-cell Lymphoma
Enrollment	6 participants
Start Date	2026-05-01
Primary Completion	2028-04-30 (estimated)
Study Completion	2028-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-01-26